GlaxoSmithKline plc / Domantis Limited

Multiple immunology/inflammation indications (RA, asthma, COPD, multiple myeloma)

Disease Overview

Domantis was a platform acquisition rather than a single-indication asset deal. Its domain antibody (dAb) technology — the smallest functional binding units of human antibodies — was being directed at rheumatoid arthritis, asthma, COPD, and multiple myeloma, targeting the same biology classes that monoclonal antibodies addressed but with the potential for inhaled, topical, and oral delivery routes that conventional mAbs cannot achieve.

Competitive Landscape

By late 2006 the antibody-engineering arms race was intense: Genentech/Roche dominated with Avastin, Herceptin, and Rituxan; Abbott had Humira; J&J/Centocor had Remicade; Amgen had Enbrel via partnership. Next-generation platforms competed to extend antibody therapeutics — Ablynx (Belgium) was advancing Nanobodies (camelid-derived single-domain antibodies), while Adnexus (later acquired by BMS in 2007) had Adnectin scaffolds. Domantis's dAbs (~11–15 kDa, vs ~150 kDa for full mAbs) were positioned to enable inhalable biologics for asthma/COPD and oral delivery for GI inflammation — formats unreachable by conventional mAbs. For GSK, the deal complemented its 2005 Cambridge Antibody Technology partnership and was framed as building a Biopharmaceuticals Centre of Excellence to compete with Roche/Genentech in next-generation biologics. PharmaTimes characterized it as part of broader big-pharma consolidation acquiring biotech to refill thinning pipelines. The dAb platform ultimately advanced multiple candidates but produced no marketed products under GSK ownership through 2024 — a cautionary outcome for platform-driven acquisitions. Source: https://pharmatimes.com/news/glaxosmithkline_to_acquire_domantis_for_230_million_995551/